We are live on
!
Find out more
AR
Advisory Research Portfolio holdings
AUM
$813M
1-Year Est. Return
36.71%
This Fund
S&P 500
This Quarter
Est. Return
+0.62%
1 Year Est. Return
+36.71%
3 Year Est. Return
+123.04%
5 Year Est. Return
+262.63%
10 Year Est. Return
+840.35%
AUM
$720M
AUM Growth
-$59.6M
(-7.6%)
Cap. Flow
-$36.5M
Cap. Flow
% of AUM
-5.06%
Top 10 Holdings %
Top 10 Hldgs %
17.21%
Holding
510
New
74
Increased
122
Reduced
203
Closed
86
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
GSK
GSK
|
+$4.08M |
| 2 |
JBTM
JBT Marel
JBTM
|
+$3.91M |
| 3 |
PRSU
Pursuit Attractions and Hospitality Inc
PRSU
|
+$3.66M |
| 4 |
Northern Oil and Gas
NOG
|
+$3.45M |
| 5 |
Devon Energy
DVN
|
+$3.09M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
DEN
Denbury Inc.
DEN
|
+$7.07M |
| 2 |
Reliance Steel & Aluminium
RS
|
+$5.93M |
| 3 |
CHX
ChampionX
CHX
|
+$4.74M |
| 4 |
Accenture
ACN
|
+$4.11M |
| 5 |
On Holding
ONON
|
+$3.96M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 21.49% |
| 2 | Consumer Discretionary | 17.64% |
| 3 | Industrials | 15.79% |
| 4 | Healthcare | 11.67% |
| 5 | Financials | 10.37% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
151
ConocoPhillips
COP
$147B
| $1.36M | 0.19% |
11,382
-348
| -3% | -$40.4K |
|
152
Johnson & Johnson
JNJ
$635B
| $1.35M | 0.19% |
8,658
-1,774
| -17% | -$293K |
|
153
Vanguard FTSE Developed Markets ETF
VEA
$226B
| $1.35M | 0.19% |
30,809
| – | – |
|
154
NCR Voyix
VYX
$1.06B
| $1.34M | 0.19% |
81,027
-522
| -0.6% | -$8.88K |
|
|
ITCI
155
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $1.32M | 0.18% |
25,333
+3,412
| +16% | +$199K |
|
156
Immunocore
IMCR
$1.78B
| $1.31M | 0.18% |
25,276
+812
| +3% | +$48.1K |
|
157
Xenon Pharmaceuticals
XENE
$6.32B
| $1.31M | 0.18% |
38,326
-6,096
| -14% | -$228K |
|
158
Arlo Technologies
ARLO
$1.4B
| $1.3M | 0.18% |
126,319
+50,082
| +66% | +$532K |
|
159
Sprouts Farmers Market
SFM
$7.04B
| $1.28M | 0.18% |
+29,943
| New | +$1.17M |
|
160
Blackbaud
BLKB
$1.5B
| $1.28M | 0.18% |
18,155
-95
| -0.5% | -$6.99K |
|
161
American Express
AXP
$223B
| $1.28M | 0.18% |
8,555
-586
| -6% | -$95.8K |
|
162
DXP Enterprises
DXPE
$2.62B
| $1.27M | 0.18% |
36,479
+25,839
| +243% | +$933K |
|
163
Fortune Brands Innovations
FBIN
$6.12B
| $1.27M | 0.18% |
20,398
-3,658
| -15% | -$251K |
|
164
Carvana
CVNA
$43.3B
| $1.25M | 0.17% |
149,240
+101,735
| +214% | +$875K |
|
165
Hershey
HSY
$35.4B
| $1.23M | 0.17% |
+6,162
| New | +$1.38M |
|
166
Sixth Street Specialty
TSLX
$1.59B
| $1.23M | 0.17% |
60,231
-5,385
| -8% | -$107K |
|
167
AptarGroup
ATR
$8.45B
| $1.23M | 0.17% |
+9,815
| New | +$1.2M |
|
|
NPKI
168
NPK International
NPKI
$1.21B
| $1.22M | 0.17% |
+177,185
| New | +$1.01M |
|
169
Hercules Capital
HTGC
$2.94B
| $1.22M | 0.17% |
74,164
-211
| -0.3% | -$3.45K |
|
170
Oaktree Specialty Lending
OCSL
$1.03B
| $1.22M | 0.17% |
60,452
-1,401
| -2% | -$28K |
|
171
Armstrong World Industries
AWI
$6.86B
| $1.21M | 0.17% |
16,825
-16,130
| -49% | -$1.2M |
|
172
NetApp
NTAP
$32.9B
| $1.2M | 0.17% |
15,785
-23,589
| -60% | -$1.82M |
|
173
Fiverr
FVRR
$376M
| $1.19M | 0.17% |
+48,831
| New | +$1.37M |
|
174
Blackstone Secured Lending
BXSL
$5.41B
| $1.19M | 0.17% |
43,562
+479
| +1% | +$13.3K |
|
175
Arhaus
ARHS
$1.12B
| $1.17M | 0.16% |
126,300
+78,610
| +165% | +$824K |
|
Similar funds
VFG
SLG
KCP
UAG
PS
CICI
RPAM
BBI
Advisory Research's Q3 2023 Portfolio in Review
As of Q3 2023, Advisory Research held 510 positions worth $720M, down 7.6% from $780M the previous quarter. Its ten largest holdings account for 17% of the portfolio.
Advisory Research withdrew a net $36.5M in Q3 2023, closing 86 positions and reducing 203 holdings. Its most notable exit was Livent Corporation, an estimated $2.81M position sold in full.
By sector, the portfolio is most concentrated in Technology at 21% of assets, down from 22% a quarter earlier, followed by Consumer Discretionary and Industrials.
Against the trend, Advisory Research opened a new position in JBT Marel worth $3.67M.
- Advisory Research's largest Q3 2023 buy was JBT Marel: 34,900 shares worth $3.67M.
- Advisory Research added most to GSK in Q3 2023, an estimated $4.08M increase.
- Advisory Research's biggest Q3 2023 reduction was Denbury Inc., cutting an estimated $7.07M.
- Advisory Research fully exited Livent Corporation in Q3 2023, selling an estimated $2.81M.
- Advisory Research's ten largest holdings make up 17% of its $720M portfolio in Q3 2023.
- Advisory Research opened 74 new positions and closed 86 in Q3 2023.
- Advisory Research's portfolio value fell 7.6% quarter-over-quarter to $720M.
Based on Advisory Research's 13F filing for Q3 2023, filed 13 Nov 2023.